← All stocks

Labcorp

LH No buying or selling
CIK 0000920148 #284 in the set updated 21 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

24 insiders · 0 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Schechter Adam H
President & CEO
102,565
$32.62M
+9.5%
EISENBERG GLENN A
Executive Vice President
37,920
$12.06M
+21.2%
Caveney Brian J
EVP, Pres of BLS, CMO & CSO
36,492
$11.61M
+29.4%
BERBERIAN LANCE
EVP, Special Advisor, Strategy
18,652
$5.93M
+17.2%
NEUPERT PETER M
Director
13,784
$4.38M
+15.4%
Kong Garheng
Director
13,739
$4.37M
+15.5%
Schroeder Mark S
EVP, Pres Diagnostics & COO
12,677
$4.03M
+151.7%
Summy Amy B.
EVP, Chief Marketing Officer
6,956
$2.21M
+75.0%
Vaughn Bryan T
EVP and President, Diagnostics
6,746
$2.15M
+31.1%
Gilliland Dwight Gary
Director
6,656
$2.12M
−23.6%
ANDERSON KERRII B
Director
6,563
$2.09M
−64.0%
van der Vaart Sandra D
EVP, Corporate Affairs
6,239
$1.98M
+65.8%
Davis Jeffrey A.
Director
5,460
$1.74M
+50.9%
GRAHAM ANITA Z
EVP, CHRO
5,185
$1.65M
+1,676%
Oyegunwa Akinbolade
EVP, CIO & CTO
5,064
$1.61M
+89.9%
Bailey Megan D.
EVP, Pres, Central Labs & Intl
4,851
$1.54M
+1,013%
Wengel Kathryn E
Director
4,133
$1.31M
+80.3%
Kyle Kathryn W
EVP, Chief Legal Officer
3,904
$1.24M
+27.9%
Meltzer Jonathan C
EVP, COO
3,620
$1.15M
+43.8%
Parham Richelle P
Director
3,366
$1.07M
−60.6%
Kliphouse Kirsten Marie
Director
3,160
$1.00M
+139.6%
Rothman Paul
Director
2,571
$817.63K
+252.2%
Wang Julia Aijun
Chief Financial Officer, EVP
1,817
$577.92K
+29,027%
Wilkinson Peter J
SVP, Chief Accounting Officer
1,770
$562.97K
+2.0%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 4
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 0
History held since 7 Sep 2016